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Introduction. Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease causing high losses on reproductive pig farms 
worldwide (1). Safe and efficacious vaccines are important tools to combat the virus. In the past, vaccination programmes have proven to be 
successful for other porcine viruses (Aujeszky's disease virus, swine fever virus). The currently available commercial vaccines give variable 
results regarding the efficacy against the genetically diverse field strains (2). To efficiently counter PRRSV, it is necessary to seek the most 
effective vaccines for sows and piglets. Recently, it was demonstrated in PRRSV-negative animals that by the use of a new procedure, an 
inactivated PRRSV vaccine could be developed that induces virus-neutralizing antibodies and offers partial protection upon homologous 
challenge (3). One of the advantages is that with this new method farm-specific vaccines can be made. In this study, the booster effect of such 
farm-specific inactivated vaccines on humoral immunity in sows with an active immunity will be compared with that of the currently 
available commercial vaccines.  
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Materials and methods. Three Belgian PRRSV isolates were used in this study originated from unrelated farms showing clinical signs 
compatible with PRRS in sows or growing pigs. At the moment of sampling, sows of the three herds were vaccinated with the EU-genotype 
attenuated vaccine (Porcilis® PRRS). Inactivated vaccines were prepared based on the farm-specific strains (07V063, 08V194 and 08V204) 
and according to the method described by Delrue et al. (2009). Twenty-five culled sows, from each PRRSV-positive farm were included in the 
experiment. A first group (n = 5 sows) served as a mock-vaccinated control group and received 1 mL RPMI in 1 mL o/w Suvaxyn. Sows of 
group 2 (n = 5 sows) were vaccinated with 1 mL BEI-inactivated Marc-145 grown virus (108 TCID50) in 1 mL o/w Suvaxyn. Sows of group 3 
(n = 5 sows) received 2 mL of a commercial European type inactivated PRRSV vaccine (Progressis®, Merial, strain P120: min 2,5 log IF 
Units). Sows of group 4 and 5 were vaccinated with the European type (Porcilis® PRRS, Intervet, 104 TCID50/ 2 mL) and the American type 
(Ingelvac® PRRS MLV, Boehringer Ingelheim, 104,9 TCID50 / 2 mL) attenuated vaccine, respectively. All vaccines in all groups were 
administered once (single shot) one week after arrival. All sows were monitored clinically. Blood was taken at 0, 1, 2 and 3 weeks after 
vaccination for determination of both IPMA and virus-neutralizing antibody titers (SN-test). Antibodies were detected against the PRRSV 
isolate, that originated from the farm where the sows were obtained.  
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Conclusion. A farm-specif ic 
vaccine, based on the circulating 
PRRSV field isolate can be one of 
the tools to control PRRSV-related 
problems. 
Results. All sows remained in good health and condition after they were vaccinated and no local or general reactions were observed. Except 
for Ingelvac® PRRS MLV, all sows developed a virus-specific antibody response after vaccination (results not shown). Compared to the 
commercial vaccines, the farm-specific inactivated vaccine induced a strong neutralizing antibody response in all three experiments (Figure 
1-3). The induction of virus-neutralizing antibodies by the commercial attenuated and inactivated PRRS vaccines agaisnt the farm-specific 
isolate was variable (Figure 1-3). 
 
 
 
 
 
 
 
 
 
 
Figure 1. PRRSV-neutralizing antibody titers (log2) 
after vaccination for group A (Mock-vaccinated control, 
black), B (BEI-inactivated 07V063, blue), C 
(Progressis®, yellow), D (Porcilis® PRRS, red) and E 
(Ingelvac® PRRS MLV, brown). Symbols represent 
individual animals and solid lines represent mean SN 
titers for each group. The dotted line marks the 
detection limit of the SN test.  
Figure 2. PRRSV-neutralizing antibody titers (log2) 
after vaccination for group A (Mock-vaccinated control, 
black), B (BEI-inactivated 08V194, blue), C 
(Progressis®, yellow), D (Porcilis® PRRS, red) and E 
(Ingelvac® PRRS MLV, brown). Symbols represent 
individual animals and solid lines represent mean SN 
titers for each group. The dotted line marks the 
detection limit of the SN test.  
Figure 3. PRRSV-neutralizing antibody titers (log2) 
after vaccination for group A (Mock-vaccinated control, 
black), B (BEI-inactivated 08V204, blue), C 
(Progressis®, yellow), D (Porcilis® PRRS, red) and E 
(Ingelvac® PRRS MLV, brown). Symbols represent 
individual animals and solid lines represent mean SN 
titers for each group. The dotted line marks the 
detection limit of the SN test.  
